The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy
Open Access
- 28 March 2017
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 116 (9), 1159-1165
- https://doi.org/10.1038/bjc.2017.57
Abstract
Transrectal prostate biopsy has limited diagnostic accuracy. Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE) was a paired-cohort confirmatory study designed to assess diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) in men requiring a repeat biopsy. All underwent 3 T mpMRI and transperineal template prostate mapping biopsies (TTPM biopsies). Multiparametric MRI was reported using Likert scores and radiologists were blinded to initial biopsies. Men were blinded to mpMRI results. Clinically significant prostate cancer was defined as Gleason ⩾4+3 and/or cancer core length ⩾6 mm. Two hundred and forty-nine had both tests with mean (s.d.) age was 62 (7) years, median (IQR) PSA 6.8 ng ml (4.98-9.50), median (IQR) number of previous biopsies 1 (1-2) and mean (s.d.) gland size 37 ml (15.5). On TTPM biopsies, 103 (41%) had clinically significant prostate cancer. Two hundred and fourteen (86%) had a positive prostate mpMRI using Likert score ⩾3; sensitivity was 97.1% (95% confidence interval (CI): 92-99), specificity 21.9% (15.5-29.5), negative predictive value (NPV) 91.4% (76.9-98.1) and positive predictive value (PPV) 46.7% (35.2-47.8). One hundred and twenty-nine (51.8%) had a positive mpMRI using Likert score ⩾4; sensitivity was 80.6% (71.6-87.7), specificity 68.5% (60.3-75.9), NPV 83.3% (75.4-89.5) and PPV 64.3% (55.4-72.6). In men advised to have a repeat prostate biopsy, prostate mpMRI could be used to safely avoid a repeat biopsy with high sensitivity for clinically significant cancers. However, such a strategy can miss some significant cancers and overdiagnose insignificant cancers depending on the mpMRI score threshold used to define which men should be biopsied.Keywords
This publication has 29 references indexed in Scilit:
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory studyThe Lancet, 2017
- The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping BiopsiesJournal of Urology, 2015
- Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancerCA: A Cancer Journal for Clinicians, 2015
- Methodological considerations in assessing the utility of imaging in early prostate cancerCurrent Opinion in Urology, 2015
- Diagnostic Performance of Initial Transperineal Template-guided Mapping Biopsy of the Prostate GlandAmerican Journal of Clinical Oncology, 2015
- Patterns of Repeat Prostate Biopsy in Contemporary Clinical PracticeJournal of Urology, 2015
- Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate CancerJAMA, 2015
- Identification of pathologically insignificant prostate cancer is not accurate in unscreened menBritish Journal of Cancer, 2014
- ESUR prostate MR guidelines 2012European Radiology, 2012
- Clinical staging of prostate cancer: a computer‐simulated study of transperineal prostate biopsyBJU International, 2005